SCHEDULE: MPM Capital Entities Reduce Stake in Werewolf Therapeutics

A group of investment entities affiliated with MPM Capital reported the sale of Werewolf Therapeutics common stock in the open market between May 6 and May 12, 2026.

Summary

• Multiple investment funds managed by MPM Capital have collectively sold 339,105 shares of Werewolf Therapeutics common stock.
• The sales occurred in the open market over five trading days from May 6, 2026, to May 12, 2026.
• Transaction prices ranged from $0.6183 to $0.7668 per share.
• The reporting persons, including MPM BioVentures 2014, L.P. and UBS Oncology Impact Fund L.P., continue to hold significant, though reduced, positions in the issuer.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral-to-negative development, as the systematic selling by a major institutional shareholder group typically exerts downward pressure on the stock price.

Positives

• The filing confirms continued, albeit reduced, investment interest from long-term institutional holders.
• The orderly nature of the open market sales suggests a managed reduction of position rather than a distressed exit.

Negatives

• The divestment by major institutional shareholders may signal a lack of confidence in the near-term upside potential of the stock.
• The selling pressure from these entities could contribute to downward volatility in the share price.

Risks

• Continued selling by major shareholders could negatively impact the stock price.
• The issuer's low share price (trading under $1.00) may pose risks related to exchange listing requirements.

Future Outlook

The filing does not provide specific forward-looking guidance regarding the issuer's business operations, focusing solely on the reporting persons' beneficial ownership changes.

Management Comments

• The reporting persons certify that the information set forth in the statement is true, complete, and correct.

Industry Context

StockSavvy.ai notes that institutional divestment in small-cap biotech firms often reflects portfolio rebalancing or the conclusion of a venture capital investment lifecycle, particularly when the issuer is trading at low valuations.

Comparison to Industry Standards

• The divestment pattern is consistent with standard venture capital exit strategies for mature portfolio companies.
• The share price levels are indicative of the broader challenges faced by early-stage oncology companies in the current market environment.

Stakeholder Impact

• Shareholders may experience increased price volatility due to the ongoing selling activity by the reporting group.

Next Steps

• Continued monitoring of further Schedule 13D filings to determine if the reporting group intends to liquidate their remaining positions.

Key Dates

Recommendation

The stock is currently experiencing selling pressure from institutional investors. A seasoned investor would likely hold to see if the selling stabilizes or if the company provides a positive catalyst to reverse the current downward trend.

Keywords

Werewolf Therapeutics, MPM Capital, Insider Selling, Schedule 13D, Biotech, Equity Divestment